Symbols / SNGX
SNGX Chart
About
Soligenix, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of products to treat rare diseases in the United States. It operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a photodynamic therapy, which has completed Phase 3 clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator (IDR) technology that is in Phase 3 clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX945, an IDR technology that is in Phase 2a study to treat aphthous ulcers in Behçet's disease; and SGX302, an IDR technology, which is in Phase 2a study for the treatment of mild-to-moderate psoriasis. Its Public Health Solutions segment engages in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase 1a, 1b, and 1c clinical trials; SGX943, a therapeutic candidate in preclinical studies for the treatment of antibiotic-resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; CiVax, a vaccine candidate for the prevention of COVID-19; and vaccine programs that target filoviruses, such as Marburg and Ebola. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in September 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 11.60M |
| Enterprise Value | 1.46M | Income | -11.17M | Sales | — |
| Book/sh | 0.77 | Cash/sh | 1.04 | Dividend Yield | — |
| Payout | 0.00% | Employees | 14 | IPO | — |
| P/E | — | Forward P/E | -1.35 | PEG | — |
| P/S | inf | P/B | 1.49 | P/C | — |
| EV/EBITDA | -0.12 | EV/Sales | — | Quick Ratio | 3.08 |
| Current Ratio | 3.18 | Debt/Eq | 5.07 | LT Debt/Eq | — |
| EPS (ttm) | -3.44 | EPS next Y | -0.85 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2025-11-07 16:00 | ROA | -69.38% |
| ROE | -165.10% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 10.09M |
| Shs Float | 9.54M | Short Float | 4.89% | Short Ratio | 2.44 |
| Short Interest | — | 52W High | 6.23 | 52W Low | 1.02 |
| Beta | 2.01 | Avg Volume | 281.24K | Volume | 89.92K |
| Target Price | $17.50 | Recom | Strong_buy | Prev Close | $1.10 |
| Price | $1.15 | Change | 4.55% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$17.50
Mean price target
2. Current target
$1.16
Latest analyst target
3. DCF / Fair value
$-10.63
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.16
Low
$10.00
High
$25.00
Mean
$17.50
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-07-16 | main | Alliance Global Partners | Buy → Buy | $6 |
- Miami BIO summit to feature Soligenix CEO on rare disease drugs - Stock Titan ue, 24 Feb 2026 12
- Soligenix Announces Pricing of $7.5 Million Public Offering - PR Newswire Fri, 26 Sep 2025 07
- $SNGX stock is down 20% today. Here's what we see in our data. - Quiver Quantitative Wed, 17 Dec 2025 08
- Soligenix to Present at BIO Investment Summit - Intellectia AI ue, 24 Feb 2026 13
- Companies Like Soligenix (NASDAQ:SNGX) Could Be Quite Risky - Yahoo Finance Wed, 20 Aug 2025 07
- Soligenix stock soars after FDA grants orphan drug designation - Investing.com Mon, 18 Aug 2025 07
- Soligenix Regains Nasdaq Compliance as of November 2025 - The Globe and Mail Wed, 19 Nov 2025 08
- Soligenix (NASDAQ:SNGX) Will Have To Spend Its Cash Wisely - simplywall.st Wed, 20 Aug 2025 07
- Soligenix Provides Shareholder Update on Rare Disease Pipeline - TipRanks hu, 12 Feb 2026 08
- Soligenix stock tumbles after pricing $7.5 million public offering - Investing.com Fri, 26 Sep 2025 07
- Soligenix Stock (SNGX) Opinions on Phase 3 HyBryteâ„¢ Safety Milestone - Quiver Quantitative ue, 07 Oct 2025 07
- 18,000 U.S. Patients: Soligenix's Rare Disease Drug SGX945 Wins Critical FDA Orphan Status for Behçet's - Stock Titan Mon, 18 Aug 2025 07
- Soligenix Drug Matches FDA-Approved Amgen Therapy In Rare Disease Trial - Yahoo Finance hu, 31 Jul 2025 07
- Why Levi Strauss Shares Are Trading Lower By Over 10%; Here Are 20 Stocks Moving Premarket - Intellectia AI hu, 19 Feb 2026 22
- Soligenix stock soars after DMC confirms safety in Phase 3 CTCL study - Investing.com ue, 07 Oct 2025 07
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 15132 | 20000 | — | Purchase at price 1.32 per share. | SCHABER CHRISTOPHER J | Chief Executive Officer | — | 2025-10-02 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 27.04K | -51.18K | -2.35K | 24.64K |
| TaxRateForCalcs | 0.05 | 0.22 | 0.08 | 0.06 |
| NormalizedEBITDA | -10.03M | -7.44M | -14.08M | -12.86M |
| TotalUnusualItems | 575.28K | -228.47K | -30.55K | 382.22K |
| TotalUnusualItemsExcludingGoodwill | 575.28K | -228.47K | -30.55K | 382.22K |
| NetIncomeFromContinuingOperationNetMinorityInterest | -8.27M | -6.14M | -13.80M | -12.55M |
| ReconciledDepreciation | 5.81K | 6.55K | 24.56K | 34.16K |
| ReconciledCostOfRevenue | 119.37K | 742.05K | 550.82K | 728.64K |
| EBITDA | -9.46M | -7.67M | -14.11M | -12.48M |
| EBIT | -9.46M | -7.67M | -14.13M | -12.51M |
| NetInterestIncome | 213.97K | -49.13K | -822.61K | -904.50K |
| InterestExpense | -213.97K | 49.13K | 822.61K | 904.50K |
| NormalizedIncome | -8.81M | -5.96M | -13.77M | -12.91M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -8.27M | -6.14M | -13.80M | -12.55M |
| TotalExpenses | 9.46M | 7.67M | 14.36M | 12.96M |
| TotalOperatingIncomeAsReported | -9.44M | -7.70M | -14.24M | -13.10M |
| DilutedAverageShares | 1.66M | 485.00K | 179.46K | 185.80K |
| BasicAverageShares | 1.66M | 485.00K | 179.46K | 185.80K |
| DilutedEPS | -4.98 | -12.66 | -76.96 | -67.54 |
| BasicEPS | -4.98 | -12.66 | -76.96 | -67.54 |
| DilutedNIAvailtoComStockholders | -8.27M | -6.14M | -13.80M | -12.55M |
| NetIncomeCommonStockholders | -8.27M | -6.14M | -13.80M | -12.55M |
| NetIncome | -8.27M | -6.14M | -13.80M | -12.55M |
| NetIncomeIncludingNoncontrollingInterests | -8.27M | -6.14M | -13.80M | -12.55M |
| NetIncomeContinuousOperations | -8.27M | -6.14M | -13.80M | -12.55M |
| TaxProvision | -409.11K | -1.77M | -1.15M | -864.74K |
| PretaxIncome | -8.68M | -7.91M | -14.95M | -13.42M |
| OtherIncomeExpense | 575.32K | -185.25K | -24.63K | 412.98K |
| OtherNonOperatingIncomeExpenses | 43.00 | 43.22K | 5.92K | 30.75K |
| SpecialIncomeCharges | 312.75K | -273.02K | 0.00 | 421.58K |
| OtherSpecialCharges | -312.75K | 273.02K | -421.58K | |
| GainOnSaleOfSecurity | 262.52K | 44.55K | -30.55K | -39.36K |
| NetNonOperatingInterestIncomeExpense | 213.97K | -49.13K | -822.61K | -904.50K |
| TotalOtherFinanceCost | -213.97K | 49.13K | ||
| InterestExpenseNonOperating | -213.97K | 49.13K | 822.61K | 904.50K |
| OperatingIncome | -9.46M | -7.67M | -14.11M | -12.92M |
| OperatingExpense | 9.35M | 6.93M | 13.81M | 12.23M |
| OtherOperatingExpenses | -93.88K | -863.14K | -831.78K | -965.69K |
| ResearchAndDevelopment | 5.22M | 3.31M | 7.94M | 8.19M |
| SellingGeneralAndAdministration | 4.22M | 4.48M | 6.69M | 5.01M |
| GeneralAndAdministrativeExpense | 4.22M | 4.48M | 6.69M | 5.01M |
| OtherGandA | 4.22M | 4.48M | 6.69M | 5.01M |
| GrossProfit | -119.37K | -742.05K | -300.82K | -695.29K |
| CostOfRevenue | 119.37K | 742.05K | 550.82K | 728.64K |
| TotalRevenue | 0.00 | 0.00 | 250.00K | 33.35K |
| OperatingRevenue | 0.00 | 0.00 | 250.00K | 33.35K |
| Line Item | 2023-12-31 | |||
|---|---|---|---|---|
| TreasurySharesNumber | 0.00 | |||
| OrdinarySharesNumber | 2.51M | 648.64K | 181.79K | 178.64K |
| ShareIssued | 2.51M | 648.64K | 181.79K | 178.64K |
| TotalDebt | 1.48M | 3.49M | 10.24M | 9.96M |
| TangibleBookValue | 4.12M | 2.52M | -2.47M | 10.72M |
| InvestedCapital | 5.49M | 5.78M | 7.43M | 20.58M |
| WorkingCapital | 3.98M | 3.36M | -2.66M | 20.28M |
| NetTangibleAssets | 4.12M | 2.52M | -2.47M | 10.72M |
| CapitalLeaseObligations | 111.86K | 233.63K | 342.57K | 106.15K |
| CommonStockEquity | 4.12M | 2.52M | -2.47M | 10.72M |
| TotalCapitalization | 4.12M | 3.53M | -2.47M | 20.58M |
| TotalEquityGrossMinorityInterest | 4.12M | 2.52M | -2.47M | 10.72M |
| StockholdersEquity | 4.12M | 2.52M | -2.47M | 10.72M |
| GainsLossesNotAffectingRetainedEarnings | 45.79K | 22.24K | 24.75K | 41.94K |
| OtherEquityAdjustments | 45.79K | 22.24K | 24.75K | 41.94K |
| RetainedEarnings | -233.97M | -225.70M | -219.56M | -205.77M |
| AdditionalPaidInCapital | 238.04M | 228.20M | 217.06M | 216.44M |
| CapitalStock | 2.51K | 649.00 | 2.91K | 2.86K |
| CommonStock | 2.51K | 649.00 | 2.91K | 2.86K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 4.85M | 7.27M | 16.75M | 16.15M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 0.00 | 1.12M | 233.67K | 9.86M |
| PreferredSecuritiesOutsideStockEquity | 0.00 | 43.00 | 0.00 | |
| LongTermDebtAndCapitalLeaseObligation | 0.00 | 1.12M | 233.63K | 9.86M |
| LongTermCapitalLeaseObligation | 0.00 | 111.86K | 233.63K | 0.00 |
| LongTermDebt | 1.01M | 9.86M | ||
| CurrentLiabilities | 4.85M | 6.15M | 16.52M | 6.29M |
| CurrentDebtAndCapitalLeaseObligation | 1.48M | 2.37M | 10.01M | 106.15K |
| CurrentCapitalLeaseObligation | 111.86K | 121.77K | 108.95K | 106.15K |
| CurrentDebt | 1.37M | 2.25M | 9.90M | |
| OtherCurrentBorrowings | 1.37M | 2.25M | 9.90M | |
| PensionandOtherPostRetirementBenefitPlansCurrent | 336.44K | 251.12K | 336.69K | 302.94K |
| PayablesAndAccruedExpenses | 3.03M | 3.53M | 6.17M | 5.88M |
| CurrentAccruedExpenses | 2.36M | 2.42M | 2.31M | 2.96M |
| Payables | 667.90K | 1.11M | 3.87M | 2.93M |
| AccountsPayable | 667.90K | 1.11M | 3.87M | 2.93M |
| TotalAssets | 8.97M | 9.80M | 14.28M | 26.87M |
| TotalNonCurrentAssets | 137.85K | 290.01K | 426.56K | 300.41K |
| OtherNonCurrentAssets | 7.75K | |||
| NonCurrentPrepaidAssets | 22.78K | 22.78K | 22.78K | 22.78K |
| NonCurrentDeferredAssets | 0.00 | 20.21K | 20.27K | |
| NonCurrentAccountsReceivable | 25.47K | 24.11K | 121.24K | |
| NetPPE | 115.08K | 241.76K | 359.47K | 128.38K |
| AccumulatedDepreciation | -121.32K | -114.77K | -167.85K | |
| GrossPPE | 115.08K | 241.76K | 474.23K | 296.22K |
| OtherProperties | 340.99K | 106.16K | ||
| MachineryFurnitureEquipment | 6.11K | 11.93K | 133.25K | 190.07K |
| BuildingsAndImprovements | 108.96K | 229.83K | 340.99K | |
| Properties | 0.00 | 0.00 | 0.00 | |
| CurrentAssets | 8.83M | 9.51M | 13.85M | 26.57M |
| OtherCurrentAssets | 905.27K | 866.01K | 274.21K | 282.90K |
| CurrentDeferredAssets | 103.85K | 0.00 | ||
| PrepaidAssets | 282.90K | |||
| Receivables | 0.00 | 195.15K | 219.33K | 242.72K |
| OtherReceivables | 195.15K | 104.20K | 103.83K | |
| AccountsReceivable | 0.00 | 115.13K | 138.89K | |
| CashCashEquivalentsAndShortTermInvestments | 7.82M | 8.45M | 13.36M | 26.04M |
| CashAndCashEquivalents | 7.82M | 8.45M | 13.36M | 26.04M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -8.40M | -8.60M | -12.66M | -11.75M |
| RepaymentOfDebt | -1.37M | -7.00M | 0.00 | -6.15K |
| IssuanceOfDebt | 0.00 | |||
| IssuanceOfCapitalStock | 5.81M | 11.59M | 79.35K | 19.71M |
| CapitalExpenditure | -13.07K | -11.79K | ||
| InterestPaidSupplementalData | 227.74K | 552.06K | 857.41K | 668.72K |
| IncomeTaxPaidSupplementalData | 42.16K | 20.73K | 16.04K | 7.73K |
| EndCashPosition | 7.82M | 8.45M | 13.36M | 26.04M |
| BeginningCashPosition | 8.45M | 13.36M | 26.04M | 18.68M |
| EffectOfExchangeRateChanges | 14.88K | 27.15K | -99.01K | 60.64K |
| ChangesInCash | -641.53K | -4.94M | -12.59M | 7.31M |
| FinancingCashFlow | 7.76M | 3.66M | 76.82K | 19.06M |
| CashFlowFromContinuingFinancingActivities | 7.76M | 3.66M | 76.82K | 19.06M |
| NetOtherFinancingCharges | -1.13M | -927.07K | -2.53K | -667.41K |
| ProceedsFromStockOptionExercised | 4.45M | 3.30K | 0.00 | 25.91K |
| NetCommonStockIssuance | 5.81M | 11.59M | 79.35K | 19.71M |
| CommonStockIssuance | 5.81M | 11.59M | 79.35K | 19.71M |
| NetIssuancePaymentsOfDebt | -1.37M | -7.00M | 0.00 | -6.15K |
| NetLongTermDebtIssuance | -1.37M | -7.00M | 0.00 | -6.15K |
| LongTermDebtPayments | -1.37M | -7.00M | 0.00 | -6.15K |
| LongTermDebtIssuance | 0.00 | |||
| InvestingCashFlow | 0.00 | -13.07K | -11.79K | |
| CashFlowFromContinuingInvestingActivities | 0.00 | -13.07K | -11.79K | |
| NetPPEPurchaseAndSale | 0.00 | -13.07K | -11.79K | |
| PurchaseOfPPE | 0.00 | -13.07K | -11.79K | |
| OperatingCashFlow | -8.40M | -8.60M | -12.65M | -11.74M |
| CashFlowFromContinuingOperatingActivities | -8.40M | -8.60M | -12.65M | -11.74M |
| ChangeInWorkingCapital | -348.41K | -3.44M | 425.11K | 651.50K |
| ChangeInOtherWorkingCapital | 33.76K | -572.16K | ||
| ChangeInOtherCurrentLiabilities | -121.77K | -108.95K | -111.12K | -116.29K |
| ChangeInPayablesAndAccruedExpense | -407.29K | -2.77M | 430.41K | 1.13M |
| ChangeInAccruedExpense | 85.33K | -85.58K | 33.76K | |
| ChangeInPayable | -492.61K | -2.69M | 396.65K | |
| ChangeInAccountPayable | -492.61K | -2.69M | 396.65K | |
| ChangeInPrepaidAssets | -39.26K | -591.80K | 8.69K | -57.43K |
| ChangeInReceivables | 219.90K | 33.89K | 97.13K | 270.12K |
| ChangesInAccountReceivables | 23.76K | 64.89K | ||
| OtherNonCashItems | 136.67K | 246.67K | 366.25K | 185.72K |
| StockBasedCompensation | 329.81K | 370.18K | 333.39K | 361.56K |
| UnrealizedGainLossOnInvestmentSecurities | -260.93K | -43.07K | ||
| DepreciationAmortizationDepletion | 5.81K | 6.55K | 24.56K | 34.16K |
| DepreciationAndAmortization | 5.81K | 6.55K | 24.56K | 34.16K |
| OperatingGainsLosses | 393.79K | -421.58K | ||
| GainLossOnInvestmentSecurities | -43.07K | |||
| NetIncomeFromContinuingOperations | -8.27M | -6.14M | -13.80M | -12.55M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for SNGX
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|